Skip to content

Collection of Additional Biological Samples From Potentially COVID-19 Patients for Monitoring of Biological Parameters Carried Out as Part of the Routine

Collection of Additional Biological Samples From Potentially COVID-19 Patients for Monitoring of Biological Parameters Carried Out as Part of the Routine

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06144333
Acronym
CEB Covid-19
Enrollment
7500
Registered
2023-11-22
Start date
2024-12-23
Completion date
2026-11-23
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SARS CoV 2 Infection

Brief summary

Patients infected with SARS-CoV-2 can present with a wide range of manifestations clinical conditions, ranging from no symptoms to serious or chronic illness. The current gold standard test for the diagnosis of COVID-19 is based on a molecular test of reverse transcription polymerase chain reaction (RT-PCR), aimed at detecting the RNA of the virus in respiratory samples such as nasopharyngeal swabs or aspirates bronchial, other methods such as antigen tests and serological detection tests IgM and IgG in response to COVID-19 viral infection, can be used for the purposes of screening in the general population. In this context of variety of existing tests, it is important to monitor the biological parameters related to COVID-19 pathology by tracking the accuracy, specificity and sensitivity of these tests in current clinical practice. This research is a collection of additional biological samples with minimal impact on the intake usual care of the patients concerned, for the monitoring of biological parameters carried out in routine on several reagent kits used for screening for the SARS-CoV-2 virus, in terms of sensitivity, specificity, positive and negative predictive values, for the implementation of indicators quality monitoring of these kits.

Interventions

DIAGNOSTIC_TESTRIPH2

* Blood sampling by capillary * Swab sampling * Blood sampling by venous punction * Salivary sample, sputum, expectoration:

Sponsors

CerbaXpert
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient over 18 years old * Patient coming for a biological analysis as part of the care for prevention, screening or monitoring of the pathogen target * Patient able to understand the information note and give a free and informed consent, on paper or digital media * Clinical patients: * Control cases (all comers or ambulatory) * Known positive for the pathology concerned * Patient hospitalized for the pathology concerned * Pregnant or breastfeeding patient * Dialysis patient

Exclusion criteria

* Patient already included in a research protocol * Patient having received medication or treatment experimental or investigational during the last four weeks before collection * Patient subject to a legal protection measure * Patient affiliated with state medical aid (AME) * Patient not affiliated to the compulsory Social Security system * Refusal or inability to provide signed informed consent * According to the investigator, the patient is not eligible for inclusion in the study

Design outcomes

Primary

MeasureTime frame
Monitoring of biological parameters carried out in routine on several reagent kits used for screening for the SARS-CoV-2 virus24 months

Contacts

Primary ContactBarbara Perniconi, Dr
bperniconi@cerbaresearch.com0142657831

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026